User profiles for Christopher C. Rowe
Christopher Cleon RoweUniversity of Melbourne Verified email at austin.org.au Cited by 69609 |
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on …
The pathophysiological process of Alzheimer’s disease (AD) is thought to begin many years
before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a …
before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a …
[HTML][HTML] NIA-AA research framework: toward a biological definition of Alzheimer's disease
In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic
recommendations for the preclinical, mild cognitive impairment, and dementia stages of …
recommendations for the preclinical, mild cognitive impairment, and dementia stages of …
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
Background Similar to most chronic diseases, Alzheimer's disease (AD) develops slowly from
a preclinical phase into a fully expressed clinical syndrome. We aimed to use longitudinal …
a preclinical phase into a fully expressed clinical syndrome. We aimed to use longitudinal …
Alzheimer's disease
Alzheimer's disease is a chronic illness with long preclinical and prodromal phases (20 years)
and an average clinical duration of 8–10 years. The disease has an estimated prevalence …
and an average clinical duration of 8–10 years. The disease has an estimated prevalence …
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis
Importance Cerebral amyloid-β aggregation is an early pathological event in Alzheimer
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
In 2018, the US National Institute on Aging and the Alzheimer's Association proposed a
purely biological definition of Alzheimer's disease that relies on biomarkers. Although the …
purely biological definition of Alzheimer's disease that relies on biomarkers. Although the …
Imaging β-amyloid burden in aging and dementia
… In this study we sought to compare [ 11 C]PIB PET as a biomarker for Aβ burden in AD,
DLB, FTD, mild cognitive impairment (MCI), and normal elderly persons with previously …
DLB, FTD, mild cognitive impairment (MCI), and normal elderly persons with previously …
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, a participant of the
worldwide Alzheimer's Disease Neuroimaging Initiative (ADNI), recruited 1112 participants …
worldwide Alzheimer's Disease Neuroimaging Initiative (ADNI), recruited 1112 participants …
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Objective Assess Aβ deposition longitudinally and explore its relationship with cognition and
disease progression. Methods Clinical follow‐up was obtained 20 ± 3 months after [ 11 C]…
disease progression. Methods Clinical follow‐up was obtained 20 ± 3 months after [ 11 C]…
β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease
β-amyloid (Aβ) deposition is pathognomic for Alzheimer's disease (AD), but may occur in
normal elderly people without apparent cognitive effect. Episodic memory impairment is an …
normal elderly people without apparent cognitive effect. Episodic memory impairment is an …